Results 111 to 120 of about 49,826 (161)

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Refractory Cirrhotic Ascites and Diabetes: Scoping Review Protocol. [PDF]

JMIR Res Protoc
Laeeq T, Kamal AM, Kasi ABU, Shabbar Banatwala UES, Baloch A, Sagaribay R, Goel V, Singh A, Batra K.   +8 more
europepmc   +1 more source

Impact of Sodium-Glucose Co-transporter 2 Inhibitors After Discharge in Patients With Heart Failure With Reduced Activities of Daily Living: A Single-Center Retrospective Cohort Study. [PDF]

Cureus
Suzuki M, Akiyama S, Saito H, Matsui H, Funakoshi R.   +4 more
europepmc   +1 more source

Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Prostate Cancer Undergoing Hormone Therapy.

JAMA Oncol
Shi R, Zhan Y, Ma R, Ali S, Yao C, Chun TTS, Ng AT, Chiu MK, Li BCW, Na R.   +9 more
europepmc   +1 more source

Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity

openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sodium‐glucose co‐transporter 2 inhibitors and hematopoiesis

Journal of Cellular Physiology, 2022
AbstractMany patients with diabetes mellitus, especially those with chronic kidney disorders, have some degree of anemia due to a spectrum of causes and underlying pathophysiologic pathways. As such, enhancement in erythropoiesis is important in these patients.
Habib Yaribeygi, Mina Maleki, Fatemeh Nasimi, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar   +5 more
openaire   +2 more sources

Sodium–glucose co-transporter-2 inhibitors

2022
Abstract This chapter studies the use of aldosterone antagonists, also known as Mineralocorticoid Receptor Antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction (LVSD) — now called heart failure with reduced ejection fraction (HF-REF) — have ...
Matthew M. Y. Lee, Kieran F. Docherty, Pardeep S. Jhund   +2 more
openaire   +1 more source

Sodium Glucose Transporter-2 Inhibitors (SGLT2Is)-TLRs Axis Modulates Diabetes

Cell Biochemistry and Biophysics, 2023
Diabetes affects millions of people worldwide and is mainly associated with impaired insulin function. To date, various oral anti-diabetic drugs have been developed, of which, the sodium glucose transporter-2 inhibitors (SGLT2Is) are of the most recent classes that have been introduced.
Amirhossein Niknejad, Yasamin Hosseini, Hedieh Sadat Shamsnia, Ayeh Sabbagh Kashani, Fatemeh Rostamian, Saeideh Momtaz, Amir Hossein Abdolghaffari   +6 more
openaire   +2 more sources

Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure

The American Journal of Cardiology, 2019
Sodium-glucose co-transporter 2 (SGLT2) receptors are primarily located in the proximal convoluted tubule of the nephron. These receptors are responsible for almost 90% to 95% of tubular reabsorption of the glucose in the nephron. In patients with diabetes mellitus, due to upregulation of SGLT2 receptors, glucose reabsorption is further increased.
Raktim K. Ghosh, Gopal Chandra Ghosh, Manasvi Gupta, Dhrubajyoti Bandyopadhyay, Tauseef Akhtar, Prakash Deedwania, Carl J. Lavie, Gregg C. Fonarow, Ashish Aneja   +8 more
openaire   +3 more sources